Rett Syndrome is a rare disorder affecting your child's ability to talk, walk, eat or breathe. Learn about its symptoms, causes & treatment options.

Neurogene’s Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June ...

Neurogene says Rett syndrome gene therapy improves clinical symptoms, but a serious adverse event causes shares to fall. Skip to main content Wednesday 25 June 2025 . BlueSky linkedin youtube ...

NEW YORK and TRUMBULL, Conn., April 30, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT ...

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares. Last week, the company reported that NGN-401 had shown ...

The patient received 3E15 vector genomes of gene therapy NGN-401 on Nov. 5 as part of the high-dose arm of Neurogene’s ongoing phase 1/2 open-label, pediatric study. She developed a fever before ...

The survey suggests that TSHA-102 could capture about two-thirds of the gene therapy market for Rett syndrome patients, potentially translating to approximately $400 million in sales at a price ...

NEW YORK and TRUMBULL, Conn., April 30, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT ...